NYSE:MRKPharmaceuticals
Merck’s Eye Drug Trial Adds New Dimension To Growth And Valuation Narrative
Merck (NYSE:MRK) has started a pivotal Phase 2b/3 trial for MK-8748, also known as Tiespectus, in neovascular age related macular degeneration.
The company is advancing a late stage ophthalmology program that includes bispecific and trispecific antibodies for retinal disease.
This development reflects a broader push beyond Merck's established focus on oncology and vaccines into eye health.
For you as an investor, this move into ophthalmology adds another therapeutic area to a business that...